YOUR PARTNER FOR CELL LINE DEVELOPMENT

Technologies to Improve Cell Line Development - Selexis SA to Present at the BIO2008 in San Diego

GENEVA, SWITZERLAND, May 07, 2008 - Selexis SA, a Swiss-based biotechnology company offering DNA based technologies and supportive services to enable significantly improved drug discovery, development, and cGMP production of biologics, announced today announced today that it will present "Technologies for Cell Line Engineering and Expression of Recombinant Proteins and Their Application Across the Biotechnology Industry" at the BIO 2008 conference in San Diego, California (June 16 -20, 2008).

Dr. Igor Fisch, CEO, will present on Thursday June 19, at 3PM as part of the *BioProcess Zone Manufacturing Series.* Selected slides from the lecture, including data on the SURE Technology Platform, which includes the patented MARtech™, will also be available following the meeting.

Presentation Abstract

In recent years, the field has begun to reexamine cell-line development systems in an effort to develop high-producing expression systems. We will discuss the latest advances in our company's platform approach affecting both the timeline and yield for MAb production in mammalian cells.

About Selexis SURE Technology:

Selexis' SURE Technology Platform, which includes the patented SGEtech™, is a unique technology that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary Selexis Genetic Elements, SGEtech™ enables cell population generation in just five weeks (after transfection) and stable cell line development in twelve weeks (after transfection to first round of cell cloning). Additionally, SGEtech™ has been found to significantly increase recombinant protein expression in mammalian cells in suspension and in serum-free up to twenty fold.

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services that enables significant improvements in the time, effort and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MABs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of epigenetic DNA based elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements™ using the SURE(sm) Cell Line Development process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

MORE INFORMATION:

Andrew F. Sandford
(617) 595-5769
andrew.sanford@selexis.com
www.Selexis.com

18, chemin des Aulx ● 1228 Plan-les-Ouates ● Geneva ● Switzerland
T +41 (0)22 308 9360 ● F +41 (0)22 308 9361
info@selexis.com ● www.selexis.com